This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M31.4 | Special Copayment Reduction: V135 (rare disease special copayment reduction) |
| B. Synonyms | Aortic arch syndrome [Takayasu] | Takayasu arteritis |
| C. Adult onset | High likelihood of first presenting in adulthood — the age of onset is mainly young adults aged 10–40 (especially women), and adult onset is virtually the mainstream. It also occurs in children, but adults are more numerous. Takayasu arteritis must be suspected in a young woman who develops resistant hypertension of unknown cause, weakened upper limb pulses or vascular bruits. |
| 1. History | 1908 first described by the Japanese ophthalmologist Takayasu Mikito → 1951 systematized by Shimizu and Sano → 1990 ACR classification criteria established → 2022 ACR/EULAR revised criteria. |
| 2. Causes | Granulomatous large-vessel vasculitis of unknown cause; T cell (CD8+ cytotoxic, NK cell)–mediated damage to the vascular media. Associated with HLA-B52. Hypothesis of infection (tuberculosis, etc.) as a trigger. |
| 3. Genetics | HLA-B*5201 and HLA-B52 show the strongest susceptibility (especially in East Asia); HLA-DRB1*0405 association. Variants associated with IL-12B and RPS9/LILRB3 have been reported. |
| 4. General epidemiology | Prevalence about 0.4–4.7 per 100,000; predominantly young women in their 10s–40s (male:female = 1:9); frequent in East Asia, India and Central and South America. Korea: several thousand registered estimated. |
| 5. Pathophysiology | CD8+ CTL and NK cells → damage to the vascular media → granuloma formation + fibrosis of the vascular media → vascular stenosis, occlusion and aneurysm. Infiltration through the vasa vasorum of the aortic adventitia. |
| 6. Symptoms | Early (active phase): fever, weight loss, fatigue, arthralgia, carotid tenderness. Late (occlusive phase): loss of pulses, upper limb blood pressure difference, retinal complications, angina, hypertension. |
| 7. Signs | Blood pressure difference between the upper limbs (≥10 mmHg); carotid and subclavian artery bruits; diminished pulses; elevated ESR and CRP. Angiography (CT/MR): stenosis and wall thickening of the aorta and its branches. |
| 8. Screening | Suspect Takayasu arteritis in a young woman under 40 with resistant hypertension, upper limb blood pressure difference, pulse asymmetry, vascular bruits or fever of unknown cause. Perform CTA or MRA. |
| 9. Diagnosis | 1990 ACR criteria (3 of 6 items: onset <40 years, limb claudication, decreased brachial artery pulse, blood pressure difference >10 mmHg, vascular bruit, arteriographic abnormality). CTA/MRA essential. |
| 10. Treatment | First line: high-dose steroids. Second line: methotrexate, azathioprine, mycophenolate. Refractory: tocilizumab (IL-6 blockade) or TNF inhibitors. Vascular intervention: PTA, stent, surgery. |
| 11. Prognosis | 5-year survival about 90% or higher; vascular complications (stroke, myocardial infarction, kidney failure, aortic aneurysm) and steroid adverse effects are the main causes of morbidity. Relapse 40–60%. |
| 12. Prevention | Relapse prevention: close monitoring during steroid tapering; tocilizumab maintenance; smoking cessation. Prevention of vascular complications: antiplatelet agents, hypertension treatment. Prevention of osteoporosis and infection. |
| 13. References | 10 major international journals and guidelines |
The history of aortic arch syndrome (Takayasu arteritis) began in 1908 when Mikito Takayasu, professor of ophthalmology at Kanazawa Medical University in Japan, presented at the Japanese Ophthalmological Society a unique wreath-shaped vascular abnormality of the retina and arteriovenous anastomosis in a 21-year-old female patient. Takayasu's colleagues Uno (Onishi) and Kaganoshima (Kagoshima) reported at the same academic meeting absent radial and ulnar artery pulsations in a similar patient, suggesting that this disease affects not only the retina but also the aorta and its major branch arteries. The nickname "pulseless disease" originated at this time.
In the 1940s–50s research on this disease was active in Japan. In 1951 Shimizu and Sano systematically described it as "pulseless disease," characterized by occlusive vasculitis of the aorta and major branches. In 1967 Takayasu's name began to be used as the disease name. As the disease was subsequently reported worldwide, it came to be recognized as a global disease occurring not only in East Asia but also in India, the Middle East, Mexico, Israel and elsewhere.
In 1990 the American College of Rheumatology (ACR) established classification criteria of 6 items. In the 1994 CHCC nomenclature it was officially classified as "Takayasu arteritis," and the same name was retained in the 2012 revision. In Korea it is managed under the name "aortic arch syndrome [Takayasu]" with ICD-10 code M31.4 and Special Copayment Reduction V135. In 2022 the ACR/EULAR presented revised classification criteria with improved diagnostic sensitivity and specificity.
The exact cause of Takayasu arteritis has not yet been fully elucidated. Autoimmune mechanisms are central, and it is understood that genetic predisposition and environmental factors (infection) act in combination.
T cell–mediated vascular damage: The main immune pathogenesis of Takayasu arteritis is damage to the vascular media and adventitia by T cells, especially CD8+ cytotoxic T cells (CTL) and natural killer (NK) cells. Inflammation beginning with infiltration of monocytes and macrophages in the vascular adventitia damages smooth muscle cells of the media, and in this process CD4+ T cells also contribute to granuloma formation. A cytotoxic mechanism via perforin and granzyme B is proposed as the main pathway of vessel wall cell death.
Association with tuberculosis (Mycobacterium tuberculosis): There is an epidemiological observation that Takayasu arteritis is more common in regions with high tuberculosis prevalence (East Asia, India, Central and South America). A hypothesis has been proposed that autoimmune vasculitis may be induced by molecular mimicry, in which the heat shock protein (HSP65) of Mycobacterium tuberculosis cross-reacts with human vascular smooth muscle cell proteins. However, a direct causal relationship has not yet been demonstrated, and the high incidence in East Asia may also be related to differences in the distribution of HLA genes.
Endothelial cell activation: Increased HLA class I expression on vascular endothelial cells promotes vascular attack by CD8+ CTLs. Increased expression of ICAM-1 and VCAM-1 on endothelial cells facilitates adhesion of inflammatory cells and penetration of the vessel wall.
Genetic research on Takayasu arteritis has been actively conducted in East Asia, centered especially on Japan and Korea, and the HLA association is the best established.
HLA-B*52 (HLA-B52): The HLA allele most strongly associated with susceptibility to Takayasu arteritis; the proportion of HLA-B52–positive patients is markedly high in Japanese, Korean and Indian patients. HLA-B52 is mainly composed of the HLA-B*5201 subtype and has been repeatedly confirmed in cohorts worldwide. It is explained that HLA-B52 presents specific vascular peptides to CD8+ T cells and amplifies the cytotoxic response.
HLA-DRB1*0405: An allele associated with CD4+ T-cell autoreactivity, reported in Japanese patients. This allele is understood to efficiently present specific vascular autoantigens to CD4+ Th1 cells and promote granuloma formation.
Non-HLA genetic variants: In genome-wide association studies (GWAS), variants of the IL12B (IL-12 p40, interleukin-12 beta subunit) gene were reported in Japanese and Turkish cohorts to be strongly associated with susceptibility to Takayasu arteritis. IL-12 is a key cytokine for Th1 differentiation and NK cell activation, and this association supports the Th1- and NK cell–mediated pathogenesis of Takayasu arteritis. Variants of the RPS9/LILRB3, MLX and DAB2IP genes have also been reported as susceptibility factors.
Takayasu arteritis is a large-vessel vasculitis that occurs frequently in young women, and its prevalence differs greatly by region. The worldwide prevalence is reported as about 0.4–4.7 per 100,000, and is relatively high in East Asia (Japan, Korea, China), India, Turkey and Central and South America.
Sex and age distribution: There is an overwhelming predominance in young women, with a male-to-female ratio of about 1:8–9. The age of onset is most commonly 10–40 years, with a mean age of onset of about 25–30 years. It also occurs in children (under 16 years) and accounts for a relatively large proportion of childhood vasculitis.
Geographic distribution: The incidence is particularly high in Japan, Korea, China, India and Mexico. According to estimates based on Korean health insurance claims data, the number of Takayasu arteritis patients in Korea is in the thousands, and there are a considerable number of patients registered under Special Copayment Reduction V135. In East Asia including Korea, the frequency of HLA-B52 is especially high, which is explained as a higher susceptibility.
Regional differences in anatomical involvement pattern: In East Asia, involvement of the aortic arch and its branches is common, while in India involvement of the abdominal aorta and renal arteries is more common. These differences are thought to reflect differences in genetic background and environmental factors.
The pathogenesis of Takayasu arteritis is understood mainly as a T cell– and NK cell–mediated cytotoxic mechanism.
Dendritic cells of the vascular adventitia and the initial immune response: It is proposed that the starting point of the initial immune response is the processing of local antigens (unidentified autoantigens or Mycobacterium tuberculosis–derived antigens) by dendritic cells located in the adventitia of the vessel wall and their presentation to T cells. T cells and monocytes penetrate into the adventitia through the vasa vasorum (small vessels within the vessel wall).
Vascular damage by CD8+ cytotoxic T cells (CTL) and NK cells: Activated CD8+ CTLs and NK cells release perforin and granzyme B and directly destroy smooth muscle cells (VSMCs) of the vascular media. CD4+ T cells (Th1, Th17) and macrophages also secrete INF-γ, TNF-α, IL-6 and IL-17 and amplify vascular inflammation.
Granuloma formation: Granulomas composed of histiocytes and multinucleated giant cells form in the media, and these granulomas destroy the vascular media. This stage corresponds clinically to the active phase.
Vascular remodeling and stenosis/dilatation: After acute inflammation, fibroblast infiltration and medial fibrosis occur, thickening the vessel wall and narrowing the lumen (stenosis). In areas of severe medial destruction, the supporting strength of the vessel wall decreases and an aneurysm forms. At stenotic sites, ischemia of downstream organs increases, and at aneurysm sites the risk of rupture increases.
The clinical course of Takayasu arteritis is traditionally divided into two stages.
Stage 1 (active inflammatory phase, prepulseless phase): Systemic inflammatory symptoms predominate, with fever, weight loss, night sweats, fatigue, myalgia and arthralgia. At this stage, carotid and subclavian artery tenderness may appear, and headache is also common. The symptoms of the active phase are nonspecific, making differentiation from tuberculosis, infection and malignancy difficult.
Stage 2 (vascular occlusive phase, pulseless phase): As a result of vascular inflammation, vascular stenosis, occlusion and dilatation (aneurysm) occur, producing symptoms of organ ischemia. Various symptoms appear depending on the vessels involved. ① Upper limb artery involvement: diminished or absent pulses, upper limb ischemia (coldness, pain, fatigue), blood pressure difference between the upper limbs (>10 mmHg). ② Carotid and vertebral artery involvement: headache, dizziness, syncope, stroke, carotid tenderness. ③ Renal artery involvement: renovascular hypertension (resistant hypertension). ④ Coronary artery involvement: angina, myocardial infarction (rare but possible). ⑤ Aortic involvement: aortic regurgitation, aortic aneurysm. ⑥ Pulmonary artery involvement: pulmonary hypertension (in some patients).
Ophthalmologic symptoms: As in Takayasu's original description, retinal lesions (wreath-shaped vascular abnormality, arteriovenous anastomosis, retinal hemorrhage) occur owing to ischemia of the carotid and ophthalmic arteries. With progression, vision loss and blindness may occur.
Pediatric Takayasu arteritis: In children, hypertension (renovascular), cardiac involvement (aortic regurgitation) and headache are more commonly the first symptoms than in adults.
The physical signs of Takayasu arteritis are determined by the distribution of the involved vessels and the degree of vascular stenosis.
Blood pressure and pulse abnormalities: A blood pressure difference between the upper limbs (>10–15 mmHg) suggests subclavian artery stenosis. Weakening or loss of the radial, ulnar and carotid pulses on one or both sides ("pulseless disease") is characteristic. A vascular bruit is heard on auscultation over sites of vascular stenosis.
Physical signs: Carotid tenderness (carotidynia) appears in the active phase. Retinal ischemic changes (ophthalmologic examination). Heart murmur (in aortic regurgitation). Upper limb blood pressure measurement may be inaccurate, and in some cases the true blood pressure must be assessed by measuring lower limb blood pressure.
Laboratory findings: Elevated ESR and CRP are indicators of the active phase, but they may be normal even when the disease is clinically active, which limits the assessment of disease activity. Leukocytosis, anemia and thrombocytosis may be observed. ANCA is negative.
Imaging findings: CT angiography (CTA) or MR angiography (MRA) shows wall thickening, stenosis, occlusion and aneurysms of the aorta and branch arteries. 18F-FDG PET-CT evaluates the metabolic activity of the vessel wall and is a sensitive test for detecting the active phase. The Numano classification (types I–VI) is used according to the pattern of involvement.
There is no screening test for Takayasu arteritis covering the whole general population. Targeted screening is needed when specific signs of vascular involvement appear in young women.
Criteria for clinical suspicion: Evaluation for large-vessel vasculitis including Takayasu arteritis should be performed in the following situations: when resistant hypertension develops in a young woman under 40; when there is a blood pressure difference (>10 mmHg) or pulse asymmetry between one or both upper limbs; when vascular bruits are auscultated over the carotid, subclavian or abdominal aortic region; when fever of unknown cause, weight loss and elevated ESR/CRP persist for weeks to months; and in a young woman who has developed retinal ischemic changes.
Initial screening tests: ESR, CRP (indicators of the active phase); complete blood count; serum creatinine (assessment of complications of renovascular hypertension); ANCA (negative — differentiation from other vasculitides); CTA or MRA (imaging of the aorta and branch arteries — assessment of wall thickening, stenosis and aneurysm); PET-CT (useful for assessing the active phase).
Importance of vascular imaging: Vascular imaging findings are the key to the diagnosis of Takayasu arteritis. CTA and MRA can noninvasively evaluate the entire aorta and branch vessels and are essential for diagnosis and assessment of disease extent. To minimize radiation exposure, MRA is considered first in young women.
The diagnosis of Takayasu arteritis is made by integrating clinical findings, blood tests and vascular imaging. Tissue biopsy is often not indispensable for diagnosis, and clinical diagnosis predominates.
1990 ACR classification criteria: A patient meeting 3 or more of the following 6 items is classified as having Takayasu arteritis (sensitivity 90.5%, specificity 97.8%). ① Age at onset <40 years. ② Limb claudication (intermittent claudication): especially of the upper limbs. ③ Decreased brachial artery pulse (one or both sides). ④ Difference in systolic blood pressure between the two arms >10 mmHg. ⑤ Vascular bruit auscultated over the subclavian artery or aorta. ⑥ Abnormality on arteriography: stenosis or occlusion of the entire aorta or its primary or secondary branch arteries (not explained by arteriosclerosis, fibromuscular dysplasia, etc.).
2022 ACR/EULAR classification criteria: Sensitivity and specificity were improved with a new scoring system that includes the pattern of vascular involvement (no upper airway involvement, large vessels), angiographic findings, age and sex, and negative ANCA.
Vascular imaging: CTA — confirms vessel wall thickening (3 mm or more), stenosis, occlusion and aneurysm. MRA — evaluates vessel wall edema and structural abnormalities without radiation. PET-CT — assesses the active phase by vessel wall metabolic activity (FDG uptake). Invasive angiography is used when an endovascular procedure is needed. For classification of disease extent, the Numano classification (type I: aortic arch branches, type IIa: ascending aorta and aortic arch, type IIb: descending thoracic aorta, type III: thoracoabdominal aorta, type IV: abdominal aorta, type V: mixed) or the modified Numano classification is used.
Treatment of Takayasu arteritis has two aspects: suppression of active inflammation and management of ischemic complications due to vascular stenosis/occlusion.
Glucocorticoids (steroids): As first-line treatment of active-phase Takayasu arteritis, treatment starts with high-dose oral prednisolone (1 mg/kg/day, maximum 60–80 mg/day) and is gradually tapered after remission is achieved. Steroids alone can induce remission in about 40–60% of patients, but relapse is common when steroids are tapered.
Steroid-sparing immunosuppressants: When remission is difficult to maintain with steroids alone or steroid adverse effects are severe, methotrexate (MTX, 15–25 mg/week), azathioprine (2 mg/kg/day), mycophenolate mofetil (MMF, 2 g/day) and others are used in combination or as steroid-sparing agents.
Biologic agents: Biologic agents are used when the response to steroids and conventional immunosuppressants is inadequate. Tocilizumab (anti-IL-6R) currently has the most evidence and suppresses vascular inflammation by blocking the interleukin-6 receptor. The Japanese TAK-T study reported an effect in preventing relapse of Takayasu arteritis. TNF-α inhibitors (infliximab, adalimumab) can also be used. Rituximab has only limited data so far. Abatacept (CTLA4-Ig) is also under investigation.
Vascular reconstruction and intervention: During remission when active inflammation is controlled, vascular procedures are performed to correct ischemic complications due to vascular stenosis/occlusion. Percutaneous angioplasty (PTA, balloon dilation) and stent placement, or vascular bypass surgery, are used. Because the restenosis rate is high when vascular procedures are performed during active inflammation, it is a principle to perform them after remission is achieved.
The prognosis of Takayasu arteritis has improved greatly compared with the past, but morbidity due to repeated relapses and long-term vascular damage remains high.
Survival: Under modern treatment, the 5-year survival rate is reported as about 90% or higher. The causes of death are mainly cardiovascular complications (stroke, myocardial infarction, heart failure), rupture of aortic aneurysm and infection (complications of immunosuppression).
Relapse: The relapse rate of Takayasu arteritis is high at about 40–60%. Relapse is most common when steroids are tapered or stopped, and repeated relapses accumulate vascular damage. Tocilizumab maintenance treatment is reported to show an effect in preventing relapse.
Accumulation of vascular damage: Progression of vascular stenosis and aneurysm formation due to repeated inflammation are the main causes of long-term morbidity. Renovascular hypertension is often difficult to control, and the risks of angina and myocardial infarction due to coronary artery involvement and of rupture of an aortic aneurysm increase.
Complications of long-term steroid administration: Takayasu arteritis occurs mainly in young women and requires treatment for decades, so osteoporosis and fractures, weight gain, diabetes mellitus and cataract due to long-term steroid administration are important problems that reduce quality of life. Switching to steroid-sparing treatment as early as possible is recommended.
Pregnancy and prognosis: Because it is a disease of young women, its relationship with pregnancy is important. Activation of Takayasu arteritis is possible during pregnancy, and the risks of renovascular hypertension and preeclampsia increase. Achieving remission before pregnancy and controlling blood pressure are important.
There is no primary prevention for Takayasu arteritis. Preventing relapse, preventing vascular complications and minimizing treatment complications are the core of clinical management.
Relapse prevention: Steroids are tapered gradually, without making the tapering rate too fast, while monitoring ESR, CRP and vascular imaging findings. If relapse is frequent during steroid-only treatment, a steroid-sparing immunosuppressant (MTX, AZA, MMF) or tocilizumab is added. Vascular activity and the occurrence of new lesions are monitored with regular PET-CT or MRA.
Prevention of vascular complications: Renovascular hypertension is treated aggressively with ACE inhibitors or ARBs. When an aortic aneurysm develops, its size and rate of progression are monitored with regular imaging and criteria for surgical indication are applied. Antiplatelet agents (low-dose aspirin) are used in some patients to prevent ischemic vascular complications (stroke, myocardial infarction).
Prevention of osteoporosis and steroid complications: Osteoporosis is prevented with calcium (1,000–1,500 mg/day), vitamin D and bisphosphonates. Blood glucose, intraocular pressure and body weight are monitored regularly.
Infection prevention: Influenza, pneumococcal and herpes zoster vaccination (given before administration of biologic agents). Consider PCP prophylaxis during the period of immunosuppression.
Pregnancy planning: In women of childbearing age, the goal is to achieve sufficient remission and blood pressure control before pregnancy, and joint management by rheumatology and obstetrics/gynecology is carried out during pregnancy.
Patient education: Patients are educated to contact the medical team immediately if symptoms of vascular complications occur, such as sudden headache, syncope, vision change (cerebrovascular ischemia), coldness or worsening pain in the upper limbs, chest pain or dyspnea (coronary or pulmonary artery involvement) and a sudden rise in blood pressure. Regular self-measurement of blood pressure (both upper limbs) and recording of the results are recommended.
Takayasu M. A case with peculiar changes of the central retinal vessels. Acta Soc Ophthalmol Jpn. 1908;12:554-555.
Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129-1134. PMID: 2202315.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. DOI: 10.1136/annrheumdis-2019-215672.
Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. DOI: 10.1136/annrheumdis-2017-211878.
Watanabe Y, Miyata T, Tanemoto K. Current Clinical Features of New Patients With Takayasu Arteritis Observed at a Cardiovascular Surgery Unit. Circulation. 2015;132(18):1701-1709.
Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis. Arthritis Rheumatol. 2022;74(12):1872-1880. DOI: 10.1002/art.42324.
Alijotas-Reig J, Messeguer-Molins A, Villardell-Tarrés M. Life-threatening pregnancy-associated Takayasu arteritis. QJM. 2018;111(7):475-481.
Youngstein T, Peters JE, Hamdulay SS, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S11-18.
Isobe M, Amano K, Arimoto J, et al. Takayasu arteritis — diagnosis and management in Japan: SCOT group recommendations. Heart Vessels. 2020;35(3):291-309.